PF 5221304

Drug Profile

PF 5221304

Alternative Names: PF05221304

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 13 Oct 2017 Pfizer plans a phase I hepatic impairment pharmacokinetics trial in USA, Belgium, Czechia and Slovakia (NCT03309202)
  • 23 Aug 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT03248882)
  • 17 Aug 2017 Pfizer plans a phase II trial for Non-alcoholic steatohepatitis (NCT03248882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top